Market Overview

UPDATE: Sterne Agee Reiterates On Intuitive Surgical Ahead Of Advisory Committee

Share:
Related ISRG
32 Stocks Moving In Friday's Mid-Day Session
Intuitive Surgical Makes New All-Time High After Q3 Beat
Intuitive Surgical Receives Composite Rating Upgrade (Investor's Business Daily)

In a report published Wednesday, Sterne Agee analyst Gregory P. Chodaczek reiterated a Neutral rating on Intuitive Surgical (NASDAQ: ISRG), and raised the price target from $380.00 to $400.00.

In the report, Sterne Agee noted, “The FDA will convene a Medical Device Advisory Committee July 10-11 based on its previous safety advisory discouraging doctors from using power morcellators to remove fibroids. We believe this outcome will move from discouragement to an FDA requirement of a ‘boxed warning' related to the risk of cancer spread using power morcellation. Although we believe this warning will negatively affect Intuitive Surgical, we maintain our Neutral rating with a new price target of $400.00.”

Intuitive Surgical closed on Tuesday at $377.60.

Latest Ratings for ISRG

DateFirmActionFromTo
Oct 2017CitigroupMaintainsBuy
Oct 2017BarclaysMaintainsOverweight
Oct 2017Morgan StanleyMaintainsOverweight

View More Analyst Ratings for ISRG
View the Latest Analyst Ratings

Posted-In: Gregory P. Chodaczek Sterne AgeeAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISRG)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...